지노믹트리

228760KOSDAQ자연과학 및 공학 연구개발업

64.8 / 100

Reference Date: 2026-07-24

Financial Score23.0 / 40

News Sentiment20.8 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 8.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GenomicTree is a South Korean company specializing in early cancer detection using biomarker-based molecular diagnostics, with its flagship product 'EarlyTect-Colon Cancer' approved in 2018. The test uses stool DNA and offers high sensitivity and rapid results, competing with traditional colonoscopies. The company is expanding globally through subsidiaries in the U.S. and a joint venture in China, though 2024 revenue declined due to the end of its coronavirus diagnostic business.

Number of Employees

76people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

2.65Industry Average 2.522.5Point

Higher than industry avg (caution)

ROE

-7.62Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.87Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 83.3

Positive
마그나인베, '3호 펀드' IRR 22.5% 청산…LP 원금 2.7배 ...
마그나인베스트먼트의 성공적인 펀드 청산으로 지노믹트리 관련 투자에 긍정적 영향 예상.
Positive
지노믹트리, 얼리텍-B 상업화 시동…美 5조 시장까지 노린다
지노믹트리의 얼리텍-B 검사가 신의료기술평가 유예 승인을 받아 상업화 단계에 진입하며 매출 확대 기대감이 높아짐.
Positive
지노믹트리, 얼리텍-B 신의료기술평가 유예 승인…8월부터 비급여 처.....
지노믹트리의 얼리텍-B 검사가 신의료기술평가 유예 승인을 받아 비급여 처방이 가능해져 시장 경쟁력 강화 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 12,290Won52-week high 32,00052-week low 10,280

1-month return5.0Point

1m +8.19% (rising)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral기업설명회(IR)개최2026-07-03